Lead Product(s): WP1122
Therapeutic Area: Infections and Infectious Diseases
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: CNS Pharmaceuticals
Deal Size: $1.0 million Upfront Cash: $0.2 million
Deal Type: Agreement March 23, 2020
CNS Pharmaceuticals has entered into an agreement with WPD Pharmaceuticals Inc for the development of several preclinical drug candidates including WP1122.